BrainsWay’s Growth Flywheel: A Platform for Interventional Psychiatry Takes Shape

BrainsWay (BWAY) has achieved significant momentum in its evolution into a broader platform for interventional psychiatry. The company’s Q2 2026 earnings demonstrate accelerating growth, expanding profitability, and increasing visibility into future revenue.

The quarterly results are impressive: $17.1 million in revenue, representing a 35% increase; operating income up over 300%; and an adjusted EBITDA margin of 20%. These numbers matter not only because they represent growth today but also because each system installed, reimbursement expansion achieved, and clinical indication developed strengthens the platform and expands long-term opportunity.

BrainsWay’s business model is built on a complex interplay between its Deep TMS systems and the broader market. As the company expands the capabilities of its platform, it increases the potential value of existing systems, creating a powerful growth flywheel with reinforcing drivers that build on one another over time.

The strength of the Deep TMS platform itself supports this strategy – backed by an extensive body of peer-reviewed clinical evidence demonstrating efficacy across various neuropsychiatric disorders. This growing body of evidence has led to multiple FDA clearances, increasing physicians’ confidence and accelerating adoption of Deep TMS.

Expanding reimbursement for Deep TMS is a critical aspect of BrainsWay’s growth strategy. Commercial payers are increasingly recognizing the value of this technology, leading to broader support and accelerated adoption. This trend has significant implications for the company’s long-term prospects, as increased reimbursement can drive higher revenue and operating leverage.

As BrainsWay continues to evolve into a broader platform for interventional psychiatry, it is building on its existing strengths while expanding its reach. The company’s leasing strategy focused on servicing enterprise customers has driven growth in remaining performance obligations, which have increased by 30% compared with the same period last year.

BrainsWay’s success sets the standard for innovation and clinical evidence in interventional psychiatry. Other companies may struggle to replicate this momentum, but they would do well to take note of BrainsWay’s commitment to expanding its platform and driving growth through its unique business model.

As investors continue to scrutinize BrainsWay’s performance, several key metrics will be worth watching: revenue growth, operating income expansion, and the company’s ability to maintain its installed base of Deep TMS systems while expanding its capabilities.